Table 3.
Patient | Androstenedione | Testosterone | Weight change | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AUC with anakinra (nmol/L) | AUC without anakinra (nmol/L) | Absolute AUC difference (nmol/L) |
Change to day 7 with anakinra (nmol/L) | Change to day 7 without anakinra (nmol/L) | Difference in change to day 7 (nmol/L) | AUC with anakinra (nmol/L) | AUC without anakinra (nmol/L) | Absolute AUC difference (nmol/L) |
Change to day 7 with anakinra (nmol/L) | Change to day 7 without anakinra (nmol/L) | Difference in change to day 7 (nmol/L) | Absolute difference in weight (kg) | Absolute difference in BMI (kg/m2) | ||
1 | 0.1 | −12.0 | +12.1 | 0.3 | −0.3 | +0.6 | 1.2 | 5.3 | −4.1 | 0.3 | 0.4 | −0.1 | +8.0 | +3.1 | |
2 | 17.3 | 205.9 | −188.6 | 3.0 | 2.7 | +0.3 | 5.0 | 29.8 | −24.8 | 1.0 | 0.1 | +0.9 | +2 | +0.7 | |
3* | −6.5 | 98.4 | −105.0 | −1.0 | 2.2 | −3.2 | −2.2 | 18.8 | −21.0 | 0.0 | 0.6 | −0.6 | +4.5 | +1.6 | |
4 | −2.0 | 40.8 | −42.8 | 0.8 | 3.1 | −2.4 | −0.5 | 11.7 | −12.2 | 0.3 | 0.4 | −0.2 | +0.7 | +0.3 | |
5 | 3.6 | −117.6 | +121.2 | 1.7 | −7.0 | +8.7 | 1.9 | −10.6 | +12.4 | 0.1 | −0.5 | +0.6 | +3.0 | +1.2 | |
6 | −3.8 | −3.3 | −0.5 | −0.3 | 1.2 | −1.5 | 0.2 | −1.8 | +2.0 | 0.0 | −0.1 | +0.1 | +2.1 | +0.9 | |
7 | 9.4 | 59.2 | −49.8 | 2.0 | 0.5 | +1.6 | 2.6 | 16.0 | −13.5 | 0.2 | 0.3 | −0.1 | +2.1 | +0.8 |
Areas under the curve (AUC) were computed by calculating the sum of changes in androgens from baseline to days 7, 14, 21, and 28. The absolute differences between AUCs were calculated by subtracting the value without anakinra from the value with anakinra, i.e., negative values indicate a reduction upon anakinra. Patient numbers do not correspond to real patient identification numbers. Patients taking metformin are marked in gray and the one patient taking progesterone is marked with an asterisk.
AUC, area under the curve; BMI, body mass index.